RxDoctor Payments Data

Fred Williams, MD

Gastroenterology · Chesterfield, MONPI 1386644326

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.6%), gifts and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Braintree Laboratories, Inc. at 24.7% of the total. That places this record below the midpoint for gastroenterology clinicians in MO, where the typical reported total is $1,415.

$556in general payments, 2019–2025

Across 31 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braintree Laboratories, Inc.$137
  • AbbVie$122
  • Lilly USA, LLC$121
  • Johnson & Johnson$99
  • Daiichi Sankyo Inc.$25
  • Ironwood Pharmaceuticals, Inc$19
  • plus $33 from 2 others
$36,405in research payments, 2019–2025

Across 5 payments — averaging $7281.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Chugai Pharmaceutical Co., Ltd.$15K
  • Eli Lilly$14K
  • Caris MPI, Inc.$8K

What the payments were for

  • Food & beverage$32058%
  • Education$9918%
  • Gifts$13725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$556 in reported general payments places this provider in the 30th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$21,553
Medicare patients
131
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine35$14,017
LinzessLinaclotide14$9,875
Colestipol Hcl28$2,852
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates36$1,946
Mesalamine ErMesalamine12$1,842
Budesonide DrBudesonide20$1,782
Pantoprazole Sodium115$1,476
Mercaptopurine12$1,252
Famotidine57$1,166
Omeprazole30$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$122$9,87514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →